Related Experiment Video
Updated: Jul 8, 2026
06:33
Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
Published on: November 10, 2023
AML1 mutations induced MDS and MDS/AML in a mouse BMT model
Naoko Watanabe-Okochi1, Jiro Kitaura, Ryoichi Ono
1Division of Cellular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, USA.
Blood
|January 15, 2008
Summary
Mouse models reveal how mutations in the AML1/RUNX1 gene contribute to myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Evi1 collaborates with AML1 mutants to accelerate MDS/AML development.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Myelodysplastic syndrome (MDS) is a stem-cell disorder with heterogeneous molecular underpinnings.
- Mutations in AML1/RUNX1 are frequently found in MDS and acute myelogenous leukemia (AML).
Purpose of the Study:
- To investigate the role of AML1/RUNX1 mutations in MDS and AML development using mouse models.
- To elucidate the collaborative mechanisms between AML1 mutants and other factors in leukemogenesis.
Main Methods:
- Mouse bone marrow transplantation (BMT) with cells transduced by AML1 mutants.
- Analysis of disease phenotypes, integration sites, and gene coexpression in transplanted mice.
Main Results:
- Transplanted mice developed MDS and MDS/AML-like symptoms.
- Evi1 collaborated with a specific AML1 mutant (AML1-D171N) to induce MDS/AML with rapid onset and distinct phenotypes.
- A C-terminal truncated AML1 mutant (S291fsX300) induced pancytopenia and erythroid dysplasia, progressing to MDS-RAEB or MDS/AML.
Conclusions:
- Developed a valuable mouse model for studying MDS and its progression to AML.
- Demonstrated collaborative roles of AML1 mutants and Evi1 in MDS/AML pathogenesis.
- Highlighted the distinct roles of different AML1 mutations in disease development.
